Latest Breaking News On - Alzamend neuro inc - Page 8 : comparemela.com

Ault Alliance (AULT) Issues Letter to Stockholders

Ault Alliance (AULT) Issues Letter to Stockholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sankt peterburgUnited statesMilton todd aultLas vegasExchange commissionSecurities exchangeAult allianceAult alliance incAdtech pharma incAlzamend neuro incBusiness wireExecutive chairmanAlzamend neuroAdtech pharmaInvestor relationsHighlands parkway

Alzamend Neuro, Inc (NASDAQ:ALZN) Short Interest Down 60 7% in August

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 216,000 shares, a decrease of 60.7% from the August 15th total of 549,900 shares. Currently, 0.4% of the shares of the stock are […]

United statesGeode capital managementAlzamend neuro incAmerica corpRenaissance technologiesCharles schwab investment management incAlzamend neuroGet free reportCapital managementSchwab investment managementAlzamend neuro dailyNasdaq alzn

Form PRER14A Timber Pharmaceuticals,

Form PRER14A Timber Pharmaceuticals,
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkState of delawareNew jerseyNew castle countyGianluca pirozziLowenstein sandlerJesper brandgaardCovington burlingSteven skolnickPhilip eickhoffJoseph luccheseCasey lindstromDavid cohenAlan mendelsohnCoherus biosciences

Alzamend Neuro, Inc (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc (NASDAQ:ALZN) Short Interest Update
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Virtu financialRenaissance technologiesBlackrock incAlzamend neuro incGeode capital managementVanguard group incAlzamend neuroGet free reportCapital managementAlzamend neuro daily

Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Safety aspects of AL001 development may qualify for pathway for FDA approval Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a.

United statesStephan jackmanDrug administrationUniversity of south florida research foundation incExchange commissionAlzamend neuro incSecurities exchangeAlzamend neuroChief executive officerSouth florida research foundationSecurities actSecurities exchange act